BRCA1 and ovarian cancer: Its cost-effectiveness was influenced significantly by the proportion of BRCA1/2 mutation carriers, the risk of developing ovary cancer in BRCA1/2 carriers, and the proportion of FH-positive individuals, while factors such as the cost of BRCA1/2 testing had a lesser impact.